Compare NBTX & CMPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBTX | CMPR |
|---|---|---|
| Founded | 2003 | 1994 |
| Country | France | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Publishing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2018 | 2005 |
| Metric | NBTX | CMPR |
|---|---|---|
| Price | $39.35 | $87.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $36.00 | ★ $86.50 |
| AVG Volume (30 Days) | 153.6K | ★ 168.3K |
| Earning Date | 03-31-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 553.45 |
| EPS | N/A | ★ 3.79 |
| Revenue | N/A | ★ $3,736,643,000.00 |
| Revenue This Year | $58.17 | $10.43 |
| Revenue Next Year | N/A | $5.46 |
| P/E Ratio | ★ N/A | $23.06 |
| Revenue Growth | N/A | ★ 9.80 |
| 52 Week Low | $8.41 | $56.34 |
| 52 Week High | $57.14 | $106.58 |
| Indicator | NBTX | CMPR |
|---|---|---|
| Relative Strength Index (RSI) | 48.30 | 39.51 |
| Support Level | $36.98 | $86.93 |
| Resistance Level | $41.06 | $105.61 |
| Average True Range (ATR) | 2.95 | 2.93 |
| MACD | -0.29 | -0.00 |
| Stochastic Oscillator | 15.87 | 25.75 |
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
Cimpress PLC helps millions of businesses build brands, stand out, and grow via customized physical marketing products and branded merchandise. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. It has five segments VistaPrint, PrintBrothers, The Print Group, National Pen, and All Other Businesses. Majority of revenue comes from VistaPrint segment which provides graphic design services, VistaCreate for do-it-yourself (DIY) design, etc. It has presence in North America, Europe, and Other. The company generates majority of revenue is from Europe.